Novartis AG NVS
145.46
2.75
1.93%
as of 25 Sep
- Market cap
- $264.3B
- P/E
- 21.8×
Follow NVS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
32.64% | 30.84% | 34.98% | 30.37% | |
| 13.65% | 13.12% | 12.39% | 11.27% | ||
ROIC |
16.85% | 16.10% | 13.97% | 13.14% | |
Return on Tangible Assets |
215.66% | 100.14% | 229.90% | 202.88% | |
Average Days of Receivables |
58.17 | 58.88 | 61.95 | 63.44 | |
Free Cash Flow per Share |
8.93 | 7.95 | 8.45 | 7.97 | |
Free Cash Flow |
17,207.00 | 15,421.00 | 16,128.00 | 15,177.00 | |
Capital Expenditures |
(3,866.00) | (3,723.00) | (3,047.00) | (3,216.00) | |
Piotroski F-Score |
6.00 | 7.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
24.90% | 20.88% | 21.08% | 19.02% | |
Accounts Receivable Turnover |
6.58 | 6.79 | 6.17 | 5.96 | |
Accounts Payable Turnover |
3.10 | 3.03 | 3.25 | 3.27 | |
Inventory Turnover |
2.17 | 2.28 | 2.30 | 2.29 | |
Average Days of Payables |
123.96 | 118.73 | 113.24 | 108.54 | |
Days of Inventory on Hand |
174.74 | 167.03 | 164.70 | 158.55 | |
Tax Rate |
(0.12) | (0.15) | (0.14) | (0.18) | |
Research and Development Expense of Revenue |
19.30% | 19.76% | 20.46% | 20.63% | |
Selling, General and Administrative Expense of Revenue |
23.61% | 23.38% | 23.56% | 23.16% | |
Share Based Compensation of Revenue |
1.90% | 1.93% | 2.01% | 2.01% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.46 | 1.37 | 1.42 | 1.44 | |
Depreciation/Fixed assets |
0.52 | 0.49 | 0.50 | 0.51 | |
Capex/Depreciation |
(0.72) | (0.71) | (0.58) | (0.59) | |
Revenue per Share |
29.27 | 29.23 | 29.64 | 29.76 | |
Operating CF per Share |
10.94 | 9.87 | 10.04 | 9.66 | |
Capex per Share |
(2.01) | (1.92) | (1.60) | (1.69) | |
Capex to Sales |
0.07 | 0.07 | 0.05 | 0.06 | |
Net Profit Margin |
25.53% | 24.67% | 23.92% | 22.50% |
Columns are period end dates